AirSculpt Technologies, Inc. (AIRS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. AirSculpt Technologies, Inc. is a national provider of body contouring procedures using its proprietary AirSculpt® method. As of August 9, 2024, the company operated 28 centers across 19 states, Canada, and the United Kingdom. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $51.0 million | $55.7 million | $98.6 million | $101.5 million |
| Net (Loss)/Income | $(3.2) million | $1.8 million | $2.8 million | $1.8 million |
| Operating Income (Loss) | $(5.0) million | $5.4 million | $6.0 million | $7.1 million |
| Adjusted EBITDA | $6.9 million | $14.6 million | $14.2 million | $24.1 million |
| Cash and Equivalents | $9.9 million | $10.3 million (Dec 2023) | $9.9 million | $20.8 million (Dec 2023) |
| Total Debt (Net) | $70.7 million | $71.6 million (Dec 2023) | $70.7 million | $71.6 million (Dec 2023) |
| Operating Cash Flow | N/A | N/A | $6.8 million | $18.5 million |
Note: Q2 2024 Net Loss was driven by a $3.7 million severance charge and increased marketing spend, offset by a tax benefit. YTD 2024 Net Income benefited from a $10.4 million reversal of stock compensation expense in Q1.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 8.4% in Q2 and 2.8% YTD compared to the prior year. Management attributes this to weaker performance in the broader aesthetic and high-end retail sectors and increased price sensitivity among consumers.
- Case Volume: Total cases performed dropped 5.7% in Q2 (3,949 vs. 4,186) and 1.7% YTD (7,695 vs. 7,826). Same-center case growth declined 14.0% in Q2.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 22.9% in Q2 to $34.3 million, primarily due to $3.7 million in severance costs and increased marketing investments ($13.1 million in Q2 vs. $9.4 million in Q2 2023).
- Equity Compensation Reversal: In Q1 2024, the company recorded a $10.4 million reversal of stock compensation expense after determining a revenue performance target was improbable. This significantly impacted YTD net income but did not affect Q2 results.
Guidance, Outlook, and Risks
- Liquidity and Covenants: The company holds $9.9 million in cash and has $5.0 million available under a revolving credit facility. Management warns that declining revenues and increased advertising costs could make it difficult to meet financial covenants (specifically leverage ratios) within the next 12 months, though they are currently in compliance.
- Leadership Change: On August 8, 2024, CEO Todd Magazine stepped down. CFO Dennis Dean was appointed Interim CEO. Mr. Magazine will provide consulting services through December 31, 2024.
- Legal Settlement: A $2.0 million settlement regarding a patient death was reached in July 2024. The amount was accrued in Q2 and is fully covered by insurance, resulting in no net income impact.
- Expansion: A new center opened in Kansas City, KS, in July 2024. The company continues to invest in de novo expansion despite current revenue headwinds.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to maintain leverage ratio covenants given the projected revenue decline and increased operating costs.
- Marketing Efficiency: Monitor Customer Acquisition Costs (CAC), which rose to $3,325 per case in Q2 2024 from $2,250 in Q2 2023, to assess the ROI of increased marketing spend.
- Same-Store Trends: Track same-center case volume, which declined 14.0% in Q2, to determine if the revenue decline is structural or cyclical.
- Leadership Transition: Assess the impact of the CEO departure and the appointment of an interim CEO on strategic execution and investor confidence.
- Insurance Coverage: Confirm the status of the $2.0 million insurance receivable related to the recent legal settlement.